Ligand Tissue Selectivity
Ligand Tissue Selectivity is a pharmacological property that refers to the preferential binding or functional activity of a ligand in specific tissue types due to the differential expression or conformation of target receptors, enabling tissue-specific therapeutic effects.
98
Publications
5.9K
Citations
528
Authors
111
Institutions
Publications per year
2017–2026
6
Parents
98
Dennis M. Kraichely, Jun Sun, John A. Katzenellenbogen et al. · Endocrinology · 2000 · 217 citations
Nicola Illing, Brigitte E. Troskie, Carol S. Nahorniak et al. · Proceedings of the National Academy of Sciences · 1999 · 193 citations · Full text
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Cory Iverson, Gary Larson, Chon Lai et al. · Cancer Research · 2009 · 183 citations · Full text
Medicine, Oncology, Pharmacology +17
1–5 of 98
528
6
h-index
6
h-index
5
h-index
4
h-index
4
h-index
1–5 of 528
111
University of Liège
Liège, Belgium
6 h-index
41 publications
1.8K citations
Université Libre de Bruxelles
Brussels, Belgium
5 h-index
37 publications
1.7K citations
Eli Lilly (United States)
Indianapolis, United States
5 h-index
48 publications
6.3K citations
Douglas Mental Health University Institute
Montreal, Canada
4 h-index
12 publications
1.3K citations
National Institute on Drug Abuse
Bethesda, United States
4 h-index
20 publications
513 citations
Utrecht University
Utrecht, The Netherlands
3 h-index
12 publications
606 citations
Douglas College
New Westminster, Canada
3 h-index
6 publications
982 citations

McGill University
Montreal, Canada
3 h-index
9 publications
376 citations
1–8 of 111
13 publications · 669 citations
13
h-index
Repository · 12 publications · 401 citations
12
h-index
10 publications · 804 citations
10
h-index
BJP · 7 publications · 364 citations
7
h-index
5 publications · 594 citations
5
h-index
1–5